Positron emission tomography imaging in lung cancer.


Journal Article

Over the past several years, positron emission tomography (PET) has become a clinically useful, noninvasive study which complements conventional imaging (chest radiographs, computed tomography [CT], and magnetic resonance imaging [MRI]) in the evaluation of patients with lung cancer. PET imaging of lung cancer is typically performed with the radiopharmaceutical 18F-2-deoxy-D-glucose (FDG), a d-glucose analog. Increased glucose metabolism by malignant cells results in increased uptake and accumulation of FDG, which serves as the basis for tumor detection. This review will focus on the current applications of FDG-PET in lung cancer patients including evaluation of focal pulmonary abnormalities, staging lung cancer, determining tumor recurrence, and in assessing prognosis.

Full Text

Duke Authors

Cited Authors

  • Patz, EF; Erasmus, JJ

Published Date

  • August 1999

Published In

Volume / Issue

  • 1 / 1

Start / End Page

  • 42 - 48

PubMed ID

  • 14725748

Pubmed Central ID

  • 14725748

International Standard Serial Number (ISSN)

  • 1525-7304

Digital Object Identifier (DOI)

  • 10.3816/clc.1999.n.002


  • eng

Conference Location

  • United States